Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Assessment of Tumor Metabolic Volume (TMV) As a Predictor of Outcomes in Patients with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)

Henry Dumke, Kellen Fitzpatrick, Tycel Phillips, Mark S Kaminski, Shannon A. Carty, Ryan A. Wilcox, Dahlia Sano, Malathi Kandarpa, Avery Polk, Benjamin L Viglianti, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 6462.

https://doi.org/10.1182/blood-2024-203822

Published: 2024

Journal Articles

Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

Anne W Beaven, Susan M. Geyer, Jonathon B. Cohen, Tycel Phillips, Travis Dockter, Priyanka A. Pophali, Gita Thanarajasingam, Gina L. Mazza, Alvaro J Alencar, Shira N. Dinner, Eric D. Hsi, Meng Welliver, Daniel Nikcevich, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard

Blood (2024) 144 (Supplement 1): 1661.3.

https://doi.org/10.1182/blood-2024-207372

Published: 2024

Journal Articles

Real-World Treatment Patterns & Characteristics of Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of US Claims (2017-2024)

John M. Burke, Ziqi Zhou, Cynthia Gutierrez, Anran Shao, Marley Boyd, Sina Noshad, Andriana Hohlbauch, Nicholas Liu, Karen Repetny, Michelle Fanale, Betsy Mitchell, Tycel Phillips

Blood (2024) 144 (Supplement 1): 7810.

https://doi.org/10.1182/blood-2024-203554

Published: 2024

Journal Articles

A Retrospective Analysis of US Commercial and Medicare Closed-Claims Databases to Evaluate Real-World Characteristics and Treatment Patterns of Patients with Diffuse Large B-Cell Lymphoma (2017-2023)

Tycel Phillips, Ziqi Zhou, Cynthia Gutierrez, Anran Shao, Marley Boyd, Sina Noshad, Andriana Hohlbauch, Nicholas Liu, Karen Repetny, Michelle Fanale, Betsy Mitchell, John M. Burke

Blood (2024) 144 (Supplement 1): 7809.

https://doi.org/10.1182/blood-2024-203380

Published: 2024

Journal Articles

Acalabrutinib, Umbralisib and Ublituximab Regimen (AU2) Demonstrates High Response Rate and Undetectable Molecular Minimal Residual Disease (MRD) in Patients (pts) with De Novo Mantle Cell Lymphoma (MCL)

Paolo Lopedote, Geoffrey Shouse, Alexandra Muir, Carly Rolender, Peter Sportelli, Hari Miskin, Lu Chen, Tycel Phillips, Alexey Danilov

Blood (2024) 144 (Supplement 1): 1633.

https://doi.org/10.1182/blood-2024-200963

Published: 2024

Journal Articles

Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)

Tycel Phillips, Mengyang Di, Taavy Miller, Jingru Wang, Amy Pierre, Gregory A. Maglinte, Erlene Kuizon Seymour, Yucai Wang

Blood (2024) 144 (Supplement 1): 3732.

https://doi.org/10.1182/blood-2024-208063

Published: 2024

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis

Michael Wang, Tadeusz Robak, Kami J. Maddocks, Tycel Phillips, Stephen D. Smith, David Gallinson, Roser Calvo, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak

Blood (2022) 140 (Supplement 1): 6477–6479.

https://doi.org/10.1182/blood-2022-157595

Published: 2022

Journal Articles

Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

Tycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, Alex Mutebi, Anthony Wang, Julie Blaedel, Katherine Kosa, Susan Martin, Mariana Sacchi, Catherine Thieblemont

Blood (2022) 140 (Supplement 1): 8022–8023.

https://doi.org/10.1182/blood-2022-159544

Published: 2022

Journal Articles

Mechanistic Insights into Immune Related Toxicities in Subjects with Relapsed/ Refractory Follicular Lymphoma Treated with Zandelisib

Binu Kandathilparambil Sasi, Stephen P. Martindale, Samantha J. Shupe, Stacey M. Fernandes, Saurabh Yadav, John-Hanson Machado, Tycel Phillips, Andrew D. Zelenetz, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 3575–3576.

https://doi.org/10.1182/blood-2022-159167

Published: 2022

Journal Articles

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2022) 140 (Supplement 1): 9443–9445.

https://doi.org/10.1182/blood-2022-158245

Published: 2022

Journal Articles

Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States

Tycel Phillips, Junhua Yu, Rajesh Kamalakar, Kalatu R. Davies, Alex Mutebi, Savreet Bains Chawla, Donald Arnette, Syed Quadri, Anthony Wang

Blood (2022) 140 (Supplement 1): 5241–5243.

https://doi.org/10.1182/blood-2022-157773

Published: 2022

Journal Articles

Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Pau Abrisqueta, Raul Cordoba, Lorenzo Falchi, Sven de Vos, Marcel Nijland, Fritz Offner, Jun Wu, Irina Bykhovski, Liwei Wang, Ali Rana, Tycel Phillips

Blood (2022) 140 (Supplement 1): 1068–1069.

https://doi.org/10.1182/blood-2022-158278

Published: 2022

Journal Articles

Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study

Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer A. Parikh, Tycel Phillips, Wayne Wang, Nishitha M. Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens

Blood (2021) 138 (Supplement 1): 392.

https://doi.org/10.1182/blood-2021-148672

Published: 2021

Journal Articles

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Blood (2021) 138 (Supplement 1): 128.

https://doi.org/10.1182/blood-2021-148778

Published: 2021

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Tycel Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Kathryn Humphrey, David Perez-Callejo, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Emma Clark, Carmelo Carlo-Stella

Blood (2021) 138 (Supplement 1): 130.

https://doi.org/10.1182/blood-2021-148949

Published: 2021

Journal Articles

Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)

Michael Wang, Tadeusz Robak, Kami J. Maddocks, Tycel Phillips, Stephen D. Smith, David Gallinson, Roser Calvo, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak

Blood (2021) 138 (Supplement 1): 2416.

https://doi.org/10.1182/blood-2021-146615

Published: 2021

Journal Articles

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Stem Cell Transplantation for Frontline, Stage III or IV Classical Hodgkin Lymphoma Based on the 5-Year Update of the ECHELON-1 Trial: A United States Perspective

Tycel Phillips, Kristen Migliaccio-Walle, Kristina S. Yu, Brian Bloudek, Nicholas Liu, Michelle A. Fanale, John M. Burke

Blood (2021) 138 (Supplement 1): 2440.

https://doi.org/10.1182/blood-2021-147308

Published: 2021

Journal Articles

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Connie Lee Batlevi, Steven I. Park, Loretta Nastoupil, Tycel Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John M. Pagel, John P. Leonard, Jay Yang, Heather O'Connor, Anthony Hamlett, Deyaa Adib, Franck Morschhauser

Blood (2021) 138 (Supplement 1): 2207.

https://doi.org/10.1182/blood-2021-148199

Published: 2021

Journal Articles

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the ECHELON-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective

John M. Burke, Kristina S. Yu, Uche Mordi, Brian Bloudek, Nicholas Liu, Michelle A. Fanale, Tycel Phillips

Blood (2021) 138 (Supplement 1): 2466.

https://doi.org/10.1182/blood-2021-148004

Published: 2021

NARROW

Assessment of Tumor Metabolic Volume (TMV) As a Predictor of Outcomes in Patients with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)

Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

Real-World Treatment Patterns & Characteristics of Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of US Claims (2017-2024)

A Retrospective Analysis of US Commercial and Medicare Closed-Claims Databases to Evaluate Real-World Characteristics and Treatment Patterns of Patients with Diffuse Large B-Cell Lymphoma (2017-2023)

Acalabrutinib, Umbralisib and Ublituximab Regimen (AU2) Demonstrates High Response Rate and Undetectable Molecular Minimal Residual Disease (MRD) in Patients (pts) with De Novo Mantle Cell Lymphoma (MCL)

Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis

Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

Mechanistic Insights into Immune Related Toxicities in Subjects with Relapsed/ Refractory Follicular Lymphoma Treated with Zandelisib

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States

Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Stem Cell Transplantation for Frontline, Stage III or IV Classical Hodgkin Lymphoma Based on the 5-Year Update of the ECHELON-1 Trial: A United States Perspective

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the ECHELON-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only